RxDoctor Payments Data

Anthony D Souza, MD

Cardiovascular Disease · Sarasota, FLNPI 1073560736

Payments from drug & device makers

$14,662in general payments, 2019–2025

Across 61 payments — averaging $240.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$10K
  • Boehringer Ingelheim$3K
  • AstraZeneca$358
  • GSK$249
  • Lilly USA, LLC$246
  • Amarin Pharma, Inc.$137
  • plus $575 from 13 others

What the payments were for

  • Speaking & faculty fees$10,99575%
  • Travel & lodging$9316%
  • Food & beverage$2,72319%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,662 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$218,637
Medicare patients
331
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$603,686
EliquisApixaban150$184,057
EntrestoSacubitril/Valsartan33$51,640
XareltoRivaroxaban41$40,955
Repatha SureclickEvolocumab34$22,057
JardianceEmpagliflozin11$10,870
Metoprolol Succinate215$3,715
Icosapent Ethyl11$2,780
Olmesartan Medoxomil83$1,838
Ezetimibe49$1,391
Rosuvastatin Calcium89$1,368
Atorvastatin Calcium102$1,124
Amlodipine Besylate153$1,011
Nifedipine ErNifedipine12$687
Enalapril Maleate14$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$97$787,744175 claims
NovartisEntresto$95$51,64033 claims
Johnson & JohnsonXarelto$10,212$40,95541 claims
Boehringer IngelheimJardiance$2,885$10,87011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →